Methods for treating attention-deficit/hyperactivity disorder

Abstract

The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

1 - 17 . (canceled) 
     
     
         18 . A method of inhibiting the progression of attention deficit hyperactivity disorder (ADHD), comprising administering a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, to a mammal in need of treatment: 
       
         
           
           
               
               
           
         
         wherein 
         R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; 
         x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; and 
         R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, phenyl, and cycloalkyl of 3 to 7 carbon atoms; or 
         R 1  and R 2  can be joined to form a 5 to 7-membered unsubstituted heterocycle, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom. 
       
     
     
         19 . The method of  claim 18 , wherein the compound having structural Formula (1) is an enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of the compound having structural Formula (1) predominates. 
     
     
         20 . The method of  claim 19 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         21 . The method of  claim 20 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         22 . The method of  claim 19 , wherein the enantiomer is (S) or (L) enantiomer as represented by Structural Formula (1a): 
       
         
           
           
               
               
           
         
       
     
     
         23 . The method of  claim 22 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         24 . The method of  claim 23 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         25 . The method of  claim 19 , wherein the enantiomer is (R) or (D) enantiomer, as represented by Structural Formula (1b): 
       
         
           
           
               
               
           
         
       
     
     
         26 . The method of  claim 25 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         27 . The method of  claim 26 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         28 . The method of  claim 25 , wherein the enantiomer is (R)-(beta-amino-benzenepropyl) carbamate. 
     
     
         29 . The method of  claim 28 , wherein the enantiomer of (R)-(beta-amino-benzenepropyl) carbamate predominates to the extent of about 90% or greater. 
     
     
         30 . The method of  claim 29 , wherein the enantiomer of (R)-(beta-amino-benzenepropyl) carbamate predominates to the extent of about 98% or greater. 
     
     
         31 . The method of  claim 18 , wherein the method further comprises administering a therapeutically effective amount of at least one other therapeutic agent for the treatment of ADHD. 
     
     
         32 . The method of  claim 18 , wherein the compound having structural Formula (1) or a pharmaceutically acceptable salt thereof and the at least one other therapeutic agent for the treatment of ADHD are administered in the same composition. 
     
     
         33 . A pharmaceutical composition for treating ADHD, comprising a compound having structural Formula (I) or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         wherein 
         R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; 
         x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; and 
         R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, phenyl, and cycloalkyl of 3 to 7 carbon atoms; or 
         R 1  and R 2  can be joined to form a 5 to 7-membered unsubstituted heterocycle, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom. 
       
     
     
         34 . A method or pharmaceutical composition substantially as shown and described.